Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugate
Biotin-Thalidomide is a biotinylated derivative of Thalidomide designed to selectively bind to the cereblon (CRBN) E3 ubiquitin ligase. This compound serves as a crucial ligand-linker conjugate for the development of proteolysis-targeting chimeras (PROTACs). Biotin-Thalidomide facilitates targeted proteasomal degradation of specific proteins, making it a valuable tool for research in targeted protein degradation and molecular biology. Its utility extends to applications in drug discovery and therapeutic development. -
CDK4/6 PROTAC Degrader
PROTAC CDK4/6 degrader 1 is a dual-targeted degrader designed to selectively degrade cyclin-dependent kinases CDK4 and CDK6. With DC50 values of 10.5 nM and 2.5 nM, this compound effectively inhibits cell proliferation in Jurkat cells, demonstrating an IC50 of 0.18 μM. The compound promotes G1 phase cell cycle arrest and triggers apoptosis, making it a valuable tool for studying cancer biology and potential therapeutic applications in CDK-related malignancies. -
CDK12/CCNK Molecular Glue
NCT02 is a molecular glue degrader that targets CDK12 through the E3 ubiquitin ligase DDB1, resulting in the ubiquitination and subsequent proteasomal degradation of its partner protein CCNK. This mechanism leads to the downregulation of CDK12, inhibiting its downstream signaling pathways. NCT02 exhibits significant biological activity by inducing apoptosis in tumor cells, arresting the cell cycle, and selectively inhibiting the proliferation of colorectal cancer cells with TP53 mutations or belonging to the CMS4 molecular subtype. Additionally, NCT02 demonstrates potential in suppressing tumor growth in both in vitro and in vivo models. -
PROTAC Linkers
Thalidomide-O-amido-PEG4-azide is a PEG-based linker designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras). This compound possesses an azide group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, it can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN functionalized compounds. This makes Thalidomide-O-amido-PEG4-azide a versatile tool in targeted protein degradation applications and chemical biology research. -
CCND1/CDK4 PROTAC Degrader
CPD-10 is a targeted CCND1 and CDK4 PROTAC degrader that effectively promotes the degradation of these proteins. Exhibiting significant anti-proliferative activity, CPD-10 induces apoptosis in cancer cell lines. It decreases the expression levels of cyclin D1, cyclin D3, CDK4, and phosphorylated Rb at serines 5807 and 811 in a dose-dependent manner, making it a valuable tool for research in cancer biology and therapeutic applications targeting cell cycle regulation. -
PROTAC EGFR Degrader
PROTAC EGFR Degrader 9 is a CRBN-based PROTAC designed to specifically target and degrade the mutant forms of the epidermal growth factor receptor (EGFR), particularly EGFRL858R/T790M/C797S. It demonstrates potent degradation activity with a DC50 of 10.2 nM and a Kd of 240.2 nM, effectively eliminating EGFR mutants while leaving wild-type EGFR unaffected. This compound serves as a valuable tool in cancer research, particularly in studies focused on targeted therapies for EGFR-driven malignancies. -
Androgen Receptor PROTAC Degrader
PROTAC AR Degrader-8 is an androgen receptor (AR) PROTAC degrader that effectively induces degradation of full-length AR (AR-FL) with DC50 values of 0.018 μM in 22Rv1 cells and 0.14 μM in LNCaP cells, as well as degrading the AR-V7 variant with a DC50 of 0.026 μM in 22Rv1 cells. This compound exhibits potent inhibition of cancer cell proliferation, with IC50 values of 0.038 μM and 1.11 μM in 22Rv1 and LNCaP cells, respectively. PROTAC AR Degrader-8 induces G2/M cell cycle arrest and promotes apoptosis in 22Rv1 cells, demonstrating significant anticancer efficacy in both murine and zebrafish models. It is a valuable tool for investigating mechanisms underlying prostate cancer and castration-resistant prostate cancer. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG2-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand combined with a two-unit polyethylene glycol (PEG) linker. This compound is designed for use in proteolysis-targeting chimera (PROTAC) applications, facilitating targeted protein degradation by promoting the interaction between the target protein and the E3 ubiquitin ligase. Its unique structure enables researchers to explore novel therapeutic strategies in cellular and molecular biology studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-azide is an E3 ligase ligand-linker conjugate featuring a Thalidomide-based cereblon ligand. It serves as an essential component in PROTAC technology, facilitating targeted protein degradation. This compound is a versatile click chemistry reagent, containing an azide group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN moieties. These properties make it valuable for various bioconjugation applications in chemical biology and therapeutic research. -
Molecular Glue Degrader
VNPP433-3β is an orally active molecular glue degrader that targets androgen receptor (AR) and its splice variants (AR-Vs), as well as MAP kinase-interacting serine/threonine protein kinases Mnk1/2. This compound induces apoptosis in cells and demonstrates significant inhibition of tumor growth in the CWR22Rv1 xenograft mouse model. VNPP433-3β is a valuable tool for investigating mechanisms in castration-resistant prostate cancer (CRPC) and pancreatic ductal adenocarcinoma (PDAC). -
PROTAC CDK4/6 degrader
HEMTAC CDK4/6 degrader 1 is a PROTAC designed to target CDK4 and CDK6 through a dual-ligand approach involving HSP90. This compound effectively induces the degradation of CDK4/6 in B16F10 melanoma cells, leading to cell cycle arrest at the G0/G1 phase and subsequent apoptosis. It serves as a vital tool for cancer research, particularly in elucidating mechanisms of CDK4/6 regulation and their role in tumor progression. Additionally, HEMTAC CDK4/6 degrader 1 features an alkyne functional group, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing compounds for advanced applications in chemical biology. -
PROTAC ERα Degrader
PROTAC ERα Degrader-4 is a selective degrader targeting estrogen receptor alpha (ERα) through the PROTAC mechanism. It exhibits potent inhibitory activity with a Ki value of 5.08 μM, effectively leading to the degradation of ERα in both Tamoxifen-sensitive and resistant ER+ breast cancer cells, as well as in ERα-mutated breast cancer cell lines. Additionally, PROTAC ERα Degrader-4 induces apoptosis, making it a valuable tool for cancer research aimed at understanding and combating ERα-driven malignancies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine 5-fluoride is a synthesized compound that functions as an E3 ligase ligand-linker conjugate, featuring the Thalidomide-derived cereblon ligand. This reagent is designed for applications in PROTAC (Proteolysis Targeting Chimeras) technology, facilitating targeted protein degradation. Its unique structure allows for effective modulation of protein levels in experimental settings, making it a valuable tool in the study of cellular processes and therapeutic development. -
PROTAC HDAC8 Degrader
SZUH280 is a selective PROTAC degrader targeting HDAC8, demonstrating a DC50 of 0.58 μM in A549 cells. It effectively induces apoptosis in cancer cells and disrupts DNA repair mechanisms, thereby enhancing cellular radiosensitivity. This compound is particularly useful for research related to cancer therapeutics and the study of epigenetic regulation. -
E3 ligase ligand-linker conjugate
Thalidomide-4-O-C6-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that plays a critical role in the targeted protein degradation (PROTAC) system, specifically in dTAG-13 applications. This compound is utilized for its ability to degrade FKBP12F36V and bromodomain and extraterminal (BET) proteins, facilitating the modulation of various cellular processes. Its utility in research allows for advancements in understanding protein function and the development of therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG3-propionic acid is an E3 ligase ligand-linker conjugate that combines the thalidomide-derived cereblon ligand with a three-unit polyethylene glycol (PEG) linker. This compound is utilized in PROTAC technology to facilitate targeted protein degradation by engaging E3 ligases. Its design enables efficient delivery of the cereblon ligand to specific cellular targets, making it valuable for research in protein homeostasis and therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate designed to facilitate the synthesis of dCBP-1. This compound acts as a potent and selective heterobifunctional degrader targeting the p300/CBP proteins, enabling targeted protein degradation for research applications in cellular processes, epigenetics, and cancer biology. Researchers can utilize this conjugate to explore pathways and mechanisms regulated by p300/CBP, advancing the understanding of transcriptional regulation and related therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C6-COOH is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with a carbon chain linker, facilitating the development of PROTAC (Proteolysis Targeting Chimera) molecules. This compound engages the cereblon protein, effectively modulating protein degradation pathways. Thalidomide-O-C6-COOH is suitable for research applications focused on targeted protein degradation and exploring the therapeutic potential of PROTAC-based strategies in various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that utilizes the Thalidomide-based cereblon ligand in conjunction with a specialized linker designed for PROTAC (Proteolysis Targeting Chimeras) applications. This compound facilitates targeted protein degradation, enabling the selective modulation of protein levels within cells. It is valuable for researchers investigating protein homeostasis, targeted therapy mechanisms, and the development of novel therapeutic strategies. -
PROTAC eEF2K Degrader
PROTAC eEF2K degrader-1 is a small molecule designed to target and induce degradation of the elongation factor 2 kinase (eEF2K). This compound has been shown to effectively promote apoptosis in MDA-MB-231 cancer cells, demonstrating its potential in cancer research. The mechanism of action involves the targeted elimination of eEF2K, providing a valuable tool for studying the role of this kinase in cellular processes and therapeutic applications. -
CCNK Molecular Glue Degrader
ZLY025 is a potent CCNK molecular glue degrader with a DC50 of 42.7 nM. This compound demonstrates significant antiproliferative effects across a range of tumor cell lines, exhibiting IC50 values between 0.08 and 2.45 μM. ZLY025 is capable of inducing apoptosis and causing G1 phase cell cycle arrest, making it a valuable tool for cancer research, particularly in the study of lung cancer. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a substrate receptor in the CRL4 ubiquitin-proteasome system. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs), offering a novel approach for selective protein degradation in various biological research applications. Its unique structure allows for the effective modulation of protein levels, making it a valuable tool in cellular biology and therapeutic research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a specialized linker utilized in PROTAC technology. This compound facilitates selective protein degradation by engaging the E3 ubiquitin ligase pathway, making it a valuable tool for investigating targeted protein modulation and therapeutic applications in cancer research and other diseases. Its structural design enhances its potential in developing targeted protein degradation strategies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C10-COOH is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived CRBN ligand. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology, enabling selective degradation of target proteins. Its biological activity is critical for research applications focused on targeted protein degradation and cellular modulation in various therapeutic contexts. -
PROTAC XPO1 Degrader
PROTAC XPO1 degrader-1 is a targeted protein degrader designed to selectively promote the degradation of XPO1. This compound demonstrates significant anti-proliferative effects, induces apoptosis, inhibits NF-κB signaling, and causes cell cycle arrest at the G1 phase. It is an important tool for researching hematological malignancies, offering insights into therapeutic strategies by modulating XPO1 levels. -
SMARCA2/4 PROTAC Degrader
PROTAC SMARCA2/4 degrader-38 is a dual-targeted PROTAC degrader designed to promote the ubiquitination and subsequent degradation of the SMARCA2 and SMARCA4 proteins. With DC50 values of 3.0 nM and 4.0 nM for SMARCA2 and SMARCA4 respectively, this compound effectively blocks the G0/G1 cell cycle phase and induces apoptosis in cancer cells. It has significant potential for use in research focused on acute myeloid leukemia (AML) and other malignancies involving these chromatin remodeling factors. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-C2-amido-C2-COOH is a ligand-linker conjugate targeting the CRBN E3 ubiquitin ligase. This compound is designed for the development of proteolysis-targeting chimeras (PROTACs), specifically facilitating the degradation of CDK2/9. It serves as a valuable tool in research focused on protein degradation pathways and the modulation of cellular processes through targeted protein elimination. -
PROTAC JAK2 Degrader
SJ1008030 is a PROTAC compound designed to selectively degrade Janus kinase 2 (JAK2). This compound exhibits potent inhibitory activity against MHH–CALL-4 cell growth, with an IC50 of 5.4 nM. SJ1008030 is valuable for research applications focusing on leukemia, facilitating the study of JAK2-related pathways and therapeutic interventions. -
PROTAC FLT3/JAK2/BRD4 Degrader
PROTAC FLT3/JAK2/BRD4 Degrader-1 is a potent PROTAC degrader that simultaneously targets FLT3, JAK2, and BRD4, exhibiting DC50 values of 5.23 nM, 0.678 nM, and 1.17 nM, respectively. It demonstrates significant antiproliferative activity against MV4;11 cells with an IC50 of 0.79 nM, inducing apoptosis in these cells. Additionally, PROTAC FLT3/JAK2/BRD4 Degrader-1 shows marked anti-tumor efficacy in MV4;11 xenograft models in NOD SCID mice. This compound is valuable for research into acute myeloid leukemia (AML). -
PROTAC FGFR1/2 Degrader
DGY-09-192 is a PROTAC degrader targeting FGFR1 and FGFR2, demonstrating DC50 values of 4.35 nM and 70 nM, respectively. This compound selectively degrades both wild-type FGFR1/2 and various FGFR2 fusion proteins, such as FGFR2-PHGDH and FGFR2-OPTN. By suppressing downstream FGFR signaling, DGY-09-192 effectively reduces the phosphorylation of key targets including FRS2 Y196 and ERK1/2 T202/Y204, making it a valuable tool for investigating FGFR-driven malignancies in both in vitro and in vivo studies. -
BCR-ABL PROTAC Degrader
Leu-PEG1-Dasa is an efficient BCR-ABL PROTAC degrader that operates through the N-terminal canonical pathway, demonstrating a DC50 of 0.48 nM. This compound utilizes a single amino acid as the E3 ligase ligand and exhibits significant anti-proliferative effects on K562 cells. Leu-PEG1-Dasa is applicable in the research of chronic myeloid leukemia (CML) and provides insights into targeted degradation mechanisms in cancer therapy. -
Ligands for Target Protein for SNIPERs
HG-7-85-01-NH2 is a synthetic ligand designed for use in SNIPER (specific and potent target protein degradation) applications. This compound features the HG-7-85-01 moiety, which inhibits ABL, and is linked to an IAP ligand to facilitate targeted protein degradation. It holds potential for advancing research in targeted therapies and cellular protein regulation. -
BCR-Abl PROTAC Degrader
GMB-805 is a potent BCR-Abl PROTAC degrader, demonstrating a DC50 of 30 nM in K562 cells. It effectively induces antiproliferative activity, making it a valuable tool for studying chronic myeloid leukemia. Additionally, GMB-805 exhibits significant anti-tumor efficacy in vivo, coupled with a favorable safety profile, highlighting its potential for therapeutic development. -
mini-PROTAC BCR-ABL Degrader
Arg-PEG1-Dasa is a mini-PROTAC designed to selectively degrade BCR-ABL, a key oncogenic driver in chronic myeloid leukemia. It demonstrates potent degradation efficacy with an EC50 of 0.85 nM, and exhibits significant antiproliferative activity in K562 cells, with an IC50 of 0.36 nM. This reagent is valuable for research applications focused on targeted therapies for BCR-ABL-driven malignancies. -
PROTAC degrader
P19As is a PROTAC degrader that targets the BCR-ABL fusion protein, exhibiting a DC50 value of approximately 200 nM for wild-type BCR-ABL. This compound effectively degrades the T315I mutant variant and demonstrates potent anti-proliferative activity in BaF3-BCR-ABL (T315I) cell lines. P19As serves as a valuable tool for investigating therapeutic strategies in chronic myeloid leukemia and acute lymphoblastic leukemia. -
BCR-ABL PROTAC Degrader
P19P is a BCR-ABL PROTAC degrader that demonstrates a DC50 value of approximately 20 nM for wild-type BCR-ABL protein. It effectively degrades various drug-resistant mutants, including T315I, E255K, H396R, and V468F, and exhibits significant anti-proliferative activity in BaF3-BCR-ABL (T315I) cells, with an IC50 of 13.1 nM against ABL (T315I). P19P is suitable for research applications related to chronic myeloid leukemia and acute lymphoblastic leukemia while showing no inhibition of vascular lumen formation in HUVEC cells. -
BCR-ABL PROTAC Degrader
SIAIS100 is a potent BCR-ABL PROTAC degrader, exhibiting a DC50 value of 2.7 nM. This compound facilitates the targeted degradation of the BCR-ABL fusion protein, making it an important tool in the study of chronic myeloid leukemia (CML). Its ability to induce proteolytic degradation offers valuable insights for therapeutic development and understanding disease mechanisms associated with CML. -
BCR-ABL PROTAC Degrader
SIAIS056 is a BCR-ABL PROTAC degrader that effectively targets and degrades BCR-ABL fusion proteins, displaying a potent DC50 value of 0.18 nM. It inhibits the BCR-ABL signaling pathway in a time-dependent manner, leading to reduced phosphorylation of BCR-ABL as well as downstream effectors like STAT5 and CRKL in K562 cells. Additionally, SIAIS056 demonstrates the ability to degrade various BCR-ABL resistance mutations and exhibits significant anti-proliferative effects, resulting in marked tumor regression in K562 xenograft models. This compound is valuable for research in leukemia. -
BCR-ABL PROTAC Degrader
P22D is a BCR-ABL PROTAC degrader designed for targeted protein degradation, exhibiting a DC50 value of approximately 10 nM for the wild-type BCR-ABL protein. This compound effectively inhibits the proliferation of K562 cells harboring the wild-type BCR-ABL, but does not exhibit activity against BaF3-BCR-ABL (T315I) cells. P22D is valuable for research on chronic myeloid leukemia and acute lymphocytic leukemia, offering insights into the mechanisms of resistance and targeted therapies. -
BCR-ABL PROTAC Degrader
Phe-PEG1-Dasa is a BCR-ABL PROTAC degrader, demonstrating a DC50 value of 1.56 nM. This compound utilizes phenylalanine as the E3 ligase ligand and triggers the N-end rule pathway to facilitate the degradation of target proteins. Phe-PEG1-Dasa effectively suppresses the proliferation of K562 leukemia cells, making it a valuable tool for research into leukemia treatment strategies. -
PROTAC FLT3-ITD Degrader
PF15 is a PROTAC designed to target FLT3 kinase through its ligands linked with CRBN. This highly selective FLT3-ITD degrader exhibits a DC50 of 76.7 nM, effectively inhibiting the proliferation of FLT3-ITD-positive cells. PF15 down-regulates the phosphorylation of FLT3 and STAT5, demonstrating significant anti-tumor activity in mouse models, making it a valuable tool for leukemia research. -
LCK PROTAC Degrader
SJ11646 is a LCK-targeting PROTAC degrader based on Dasatinib, exhibiting a DC50 of 0.00838 pM. This compound demonstrates potent cytotoxic effects against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples, effectively prolonging LCK signaling suppression and inducing apoptosis in T-ALL. Additionally, SJ11646 binds with high affinity to 51 human kinases, including ABL1, KIT, and DDR1, and shows enhanced antileukemic efficacy in T-ALL mouse models, making it a valuable tool for research into novel therapeutic strategies for leukemia. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate, featuring a Thalidomide-based cereblon ligand integrated with a flexible linker tailored for PROTAC (Proteolysis Targeting Chimera) applications. This compound demonstrates the capacity to facilitate targeted protein degradation by recruiting E3 ligases to specific substrates, thereby enhancing the control of protein levels in cellular systems. It is valuable for research in targeted therapy and protein regulation studies. -
Ligands for E3 Ligase
Thalidomide-5-NH-CH2-COO(t-Bu) serves as a ligand for the E3 ubiquitin ligase Cereblon (CRBN). This derivative of Thalidomide features a t-Bu protecting group, which can be removed under acidic conditions, facilitating the development of proteolysis-targeting chimeras (PROTACs). Thalidomide-5-NH-CH2-COO(t-Bu) is crucial for synthesizing CRBN-based PROTACs, enabling targeted protein degradation for various biological research applications. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-NH-PEG1-COOH TFA functions as an E3 Ligase Ligand-Linker Conjugate that targets Cereblon (CRBN). This compound selectively recruits the CRBN protein, facilitating targeted protein degradation pathways. Thalidomide-4-NH-PEG1-COOH TFA is a critical intermediate in the synthesis of CRBN-based PROTAC molecules, making it valuable for research into novel therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG1-C2-NH2 is an E3 ligase ligand-linker conjugate designed for use in targeted protein degradation applications. This compound features a Thalidomide-derived cereblon ligand that facilitates the recruitment of specific substrates to the ubiquitin-proteasome system. Its linker component is compatible with PROTAC technology, making it a valuable tool for researchers investigating therapeutic strategies aimed at modulating protein levels within cells. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C8-NH2 is a synthetic E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand. This compound serves as a valuable tool in PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted degradation of specific proteins in cellular systems. It is widely utilized in studies focusing on protein homeostasis, disease modeling, and therapeutic development in various fields including cancer research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C8-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with a C8 amido linker. This compound is specifically designed for use in PROTAC technology, facilitating targeted protein degradation by recruiting E3 ligases to specific substrates. Its biochemical properties make it suitable for investigating protein modulation and therapeutic applications in cellular research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG2-C2-NH2 is a conjugate designed for E3 ligase targeting, featuring a Thalidomide-derived cereblon ligand combined with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation by engaging E3 ligases through PROTAC technology. It is suitable for research applications aimed at exploring protein regulation and therapeutic interventions in various diseases. -
PROTAC CDK4/6/9 Degrader
PROTAC CDK4/6/9 Degrader 1 is a targeted protein degradation agent that specifically degrades cyclin-dependent kinases CDK4, CDK6, and CDK9. This compound effectively inhibits the proliferation of triple-negative breast cancer (TNBC) cells by inducing G1 phase arrest, promoting apoptosis, and suppressing cellular migration and invasion. PROTAC CDK4/6/9 Degrader 1 serves as a valuable tool for studying the role of these kinases in TNBC and may support the development of novel therapeutic strategies aimed at this aggressive cancer subtype.
